Innate Pharma (IPHA) Scheduled to Post Earnings on Tuesday

Innate Pharma (NASDAQ:IPHA) will be issuing its quarterly earnings data before the market opens on Tuesday, May 14th.

Innate Pharma Price Performance

NASDAQ IPHA opened at $2.63 on Wednesday. Innate Pharma has a one year low of $1.81 and a one year high of $3.57. The company has a 50-day simple moving average of $2.52 and a 200-day simple moving average of $2.55. The company has a quick ratio of 3.73, a current ratio of 3.73 and a debt-to-equity ratio of 0.60.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and set a $11.50 price target on shares of Innate Pharma in a research report on Thursday, April 11th.

Innate Pharma Company Profile

Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.